Analysts Expect China Biologic Products Holdings, Inc. (CBPO) Will Post Earnings of $1.11 Per Share

Brokerages expect China Biologic Products Holdings, Inc. (NASDAQ:CBPO) to announce earnings per share (EPS) of $1.11 for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have provided estimates for China Biologic Products’ earnings. China Biologic Products posted earnings per share of $0.95 in the same quarter last year, which would suggest a positive year-over-year growth rate of 16.8%. The company is scheduled to announce its next quarterly earnings report on Thursday, February 22nd.

According to Zacks, analysts expect that China Biologic Products will report full-year earnings of $5.22 per share for the current financial year, with EPS estimates ranging from $5.17 to $5.26. For the next year, analysts forecast that the firm will post earnings of $5.75 per share, with EPS estimates ranging from $5.49 to $6.00. Zacks’ earnings per share averages are an average based on a survey of research analysts that follow China Biologic Products.

A number of research firms recently commented on CBPO. Zacks Investment Research upgraded shares of China Biologic Products from a “sell” rating to a “hold” rating in a report on Wednesday, November 15th. BidaskClub upgraded shares of China Biologic Products from a “strong sell” rating to a “sell” rating in a report on Wednesday, December 20th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and two have given a buy rating to the company. The stock presently has a consensus rating of “Hold” and an average target price of $137.50.

China Biologic Products (CBPO) traded down $0.32 during trading hours on Friday, reaching $78.77. 67,989 shares of the company were exchanged, compared to its average volume of 150,438. China Biologic Products has a 52 week low of $72.21 and a 52 week high of $120.46. The company has a market cap of $2,183.62, a price-to-earnings ratio of 19.84, a P/E/G ratio of 1.29 and a beta of 1.78.

A number of institutional investors have recently modified their holdings of the business. AXA increased its position in China Biologic Products by 35.9% during the 3rd quarter. AXA now owns 128,220 shares of the biopharmaceutical company’s stock valued at $11,831,000 after purchasing an additional 33,886 shares during the period. California Public Employees Retirement System increased its position in China Biologic Products by 51.7% during the 3rd quarter. California Public Employees Retirement System now owns 44,757 shares of the biopharmaceutical company’s stock valued at $4,130,000 after purchasing an additional 15,257 shares during the period. Cubist Systematic Strategies LLC increased its position in China Biologic Products by 73.2% during the 3rd quarter. Cubist Systematic Strategies LLC now owns 4,617 shares of the biopharmaceutical company’s stock valued at $426,000 after purchasing an additional 1,952 shares during the period. Cornerstone Capital Management Holdings LLC. increased its position in China Biologic Products by 31.0% during the 3rd quarter. Cornerstone Capital Management Holdings LLC. now owns 363,190 shares of the biopharmaceutical company’s stock valued at $33,511,000 after purchasing an additional 85,909 shares during the period. Finally, Temasek Holdings Private Ltd purchased a new position in China Biologic Products during the 3rd quarter valued at $3,414,000. 65.13% of the stock is currently owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION NOTICE: “Analysts Expect China Biologic Products Holdings, Inc. (CBPO) Will Post Earnings of $1.11 Per Share” was published by The Lincolnian Online and is owned by of The Lincolnian Online. If you are viewing this piece on another publication, it was illegally copied and republished in violation of U.S. and international copyright laws. The original version of this piece can be viewed at https://www.thelincolnianonline.com/2018/01/14/analysts-expect-china-biologic-products-holdings-inc-cbpo-will-post-earnings-of-1-11-per-share-updated-updated.html.

About China Biologic Products

Get a free copy of the Zacks research report on China Biologic Products (CBPO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for China Biologic Products (NASDAQ:CBPO)

Receive News & Ratings for China Biologic Products Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for China Biologic Products and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply